Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma

This is an interventional treatment trial for Extranodal NK/T-cell Lymphoma, Nasal Type focused on measuring Avastin+ GemAOD, first line chemotherapy, NK/T-cell Lymphoma Read More

Inclusion Criteria:

• Histologic diagnosis of NK/T Cell Lymphoma;
• Age:18-80 years;
• Eastern Cooperative Oncology Group (ECOG) status 0-3, Estimated survival time > 3 months;
• Normal haematological, liver and renal function (WBC count≥4×109/L, Hemoglobin≥100g/L, platelet count≥100×109/L, bilirubin<1.5×ULN, Alanine transaminase (ALT) or Aspartate Aminotransferase (AST)<2.5×ULN, serum creatinine<1.5×ULN), normal coagulation function and cardiac function;
• Appreciable and measurable lesions ;
• No history of other malignancies;
• No previous treatments including chemotherapy, radiotherapy, targeted therapy or stem cell transplantation;
• No other serious diseases which conflict with the treatment in the present trial;
• No concurrent treatments that conflict with the treatments in the present trial(including steroid drugs);
• Voluntary participation and signed the informed consent.

Exclusion Criteria:

• The patients had the conditions below: clinically significant ventricular tachycardia (VT), atrial fibrillation (AF), heart block, myocardial infarction (MI), congestive heart failure (CHF), symptomatic coronary artery heart disease requiring medication;
• The patients suffered from organ transplant
• The patients participated in other clinical trials within the 30 days before enrollment or who are participating in other clinical studies;
• The patients with active bleeding or new thrombotic disease, who are taking anticoagulant drugs or with a history of bleeding tendencies;
• The patients suffered before surgery less than four weeks, or after less than six weeks;
• The patients with major vascular invasion;
• The patients with abnormal liver function (total bilirubin> 1.5 times the normal value, ALT / AST> 2.5 times normal), abnormal renal function (serum creatinine> 1.5 times normal), blood abnormalities (absolute neutrophil count <1.5 × 109 / L, platelets <80 × 109 / L, hemoglobin <90g /L) ;
• The patients with moderate to severe proteinuria;
• Severe hypertension,BP≥160/100mmHg;
• The patients with mentally ill / unable to obtain informed consent;
• The patients with drug addiction, alcohol abuse which affects the long-term evaluation of test results;
• The patients in pregnancy, lactation and women of childbearing age who do not want to take contraceptive measures subjects;
• Clinical and laboratory support brain metastases;
• The patients with a history of allergy to test drug;
• The patients not suitable to participate in the investigator judged by researchers.